Development of a highly sensitive and specific carboxy-terminal human pancreastatin assay to monitor neuroendocrine tumor behavior

Pancreas

Volumn 39, Issue 5, 2010, Pages 611-616

  O'Dorisio, Thomas M ^a   Krutzik, Siegfried R ^b   Woltering, Eugene A ^c   Lindholm, Erika ^d   Joseph, Saju ^c   Gandolfi, Abby E ^c   Wang, Yi Zarn ^c   Boudreaux, J Phillip ^c   Vinik, Aaron I ^e   Go, Vay Liang W ^f   Howe, James R ^g   Halfdanarson, Thor ^g   O'Dorisio, M Sue ^g   Mamikunian, Gregg ^b  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b Inter Science Institute   (United States)

^c LOUISIANA STATE UNIV HLTH SCI C   (United States)

^d LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF IOWA   (United States)

Author keywords

biomarkers; carcinoid; chemoembolization; chromogranins; cytoreduction; embolization; islet cell tumors; neuroendocrine tumors; pancreastatin assay

Indexed keywords

CHROMOGRANIN A; OCTREOTIDE; PANCREASTATIN; PANCREAS HORMONE; TUMOR MARKER;

ADULT; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; LIVER TUMOR; MALE; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; BLOOD; COMPARATIVE STUDY; EVALUATION STUDY; MIDDLE AGED; PATHOLOGY; REPRODUCIBILITY;

CHROMOGRANIN A; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC HORMONES; RADIOIMMUNOASSAY; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 77954099329     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181c68d7a     Document Type: Review

References (19)

1. O'Connor DT, Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med. 1986;314: 1145-1151.
2. Kolby L, Bernhardt P, Swärd C, et al. Chromogranin A as a determinant of midgut carcinoid tumour volume. Regul Pept. 2004;120:269-273.
3. Nobels FRE, Kwekkeboom DV, Bouillon R, et al. Chromogranin A: its clinical value as marker of neuroendocrine tumors. Eur J Clin Invest. 1998;8:431-440.
4. Sondenaa K, Sen J, Heinle F, et al. Chromogranin A, a marker of the therapeutic success of resection of neuroendocrine liver metastases: preliminary report. World J Surg. 2004;28:890-895.
5. Udupi V, Lee HM, Kurosky A, et al. Prohormone convertase-1 is essential for conversion of chromogranin A to pancreastatin. Regul Pept. 1999;83:123-127.
6. Calhoun K, Toth-Fejel S, Cheek J, et al. Serum peptide profiles in patients with carcinoid tumors. Am J Surg. 2003;186:28-31.
7. Iacangelo AL, Fischer-Colbrie R, Koller KJ, et al. The sequence of porcine chromogranin A messenger RNA demonstrates chromogranin A can serve as the precursor for the biologically active hormone, pancreastatin. Endocrinology. 1988;122:2339-2341.
8. O'Connor DT, Cadman PE, Smiley C, et al. Pancreastatin: multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism. J Clin Endocrinol Metabol. 2005;90:5414-5425.
9. Tatemoto K, Efendic S, Mutt V, et al. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature. 1986;324:476-478.
10. Kogner P, Bjellerup P, Svensson T, et al. Pancreastatin immunoreactivity in favourable childhood neuroblastoma and ganglioneuroma. Eur J Cancer. 1995;31A:557-560.
11. Desai DC, O'Dorisio TM, Schirmer WJ, et al. Serum pancreastatin levels predict response to hepatic artery chemoembolization and somatostatin analogue therapy in metastatic neuroendocrine tumors. Regul Pept. 2001;96:113-117.
12. O'Dorisio MS, Hauger M, O'Dorisio TM. Age-dependent levels of neuropeptides in normal children. Regul Pept. 2002;109:189-192.
13. Bloomston M, Al-Saif O, Klemanski D, et al. Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned. J Gastrointest Surg. 2007;11:264-271.
14. Woltering EA, Hilton RS, Zolfoghary CM, et al. Validation of serum versus plasma measurements of chromogranin A levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin A levels and symptom frequency. Pancreas. 2006;33:250-254.
15. Arnold R, Wilke A, Rinke A, et al. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumor. Clin Gastroenterol Hepatol. 2008;6:820-827.
16. Stridsberg M, Erikkson B, Oberg K, et al. A comparison between three commercial kits for chromogranin A measurements. J Endocrinol. 2003;177:337-341.
17. Sanchez-Margalet V, Lucas M, Goberna R. Pancreastatin: further evidence for its consideration as a regulatory peptide. J Mol Endocrinol. 1996;16:1-8.
18. Stronge RL, Turner GB, Johnston BT, et al. A rapid rise in circulating pancreastatin in response to somatostatin analogue therapy is associated with poor survival in patients with neuroendocrine tumours. Ann Clin Biochem. 2008;45:560-566.
19. Zhang K, Rao F, Wen G, et al. Catecholamine storage vesicles and the metabolic syndrome: the role of the chromogranin A fragment pancreastatin. Diab Obes Metab. 2006;8:621-623.